Table 2 Diagnostic analysis of the urine-NMR metabolomics samples in detecting colorectal neoplasia.
Healthy control (n = 156) | CRNa (n = 92) | Model R2/Q2 | Specificity | Sensitivity | |||||
|---|---|---|---|---|---|---|---|---|---|
Model | Validation | Model | Validation | ||||||
All CRN* | Samples | 104 | 52 | 62 | 30 | R2 | 0.864 | 96.2% | 100% |
Prediction | 50/52 | 30/30 | Q2 | 0.714 | |||||
Pre-invasive CRNb | Samples | 104 | 52 | 40 | 20 | R2 | 0.845 | 96.2% | 95% |
Prediction | 50/52 | 19/20 | Q2 | 0.732 | |||||
Stage 0 CRCc | Samples | 104 | 52 | 17 | 7 | R2 | 0.830 | 98.1% | 100% |
Prediction | 51/52 | 7/7 | Q2 | 0.644 | |||||
Advanced adenoma | Samples | 104 | 52 | 24 | 12 | R2 | 0.727 | 100% | 75% |
Prediction | 52/52 | 9/12 | Q2 | 0.634 | |||||
